Share on StockTwits

Repligen Corp. (NASDAQ:RGEN) was the target of some unusual options trading activity on Wednesday. Traders bought 611 put options on the stock, reports. This represents an increase of 536% compared to the typical daily volume of 96 put options.

A number of research firms have recently commented on RGEN. Analysts at Janney Montgomery Scott initiated coverage on shares of Repligen Corp. in a research note on Thursday, June 26th. They set a “buy” rating and a $26.00 price target on the stock. Analysts at Jefferies Group raised their price target on shares of Repligen Corp. from $20.00 to $22.00 in a research note on Wednesday, June 4th. They now have a “buy” rating on the stock.

Repligen Corp. (NASDAQ:RGEN) traded down 1.07% on Wednesday, hitting $20.31. The stock had a trading volume of 508,875 shares. Repligen Corp. has a 52-week low of $9.41 and a 52-week high of $24.68. The stock has a 50-day moving average of $22.57 and a 200-day moving average of $17.88. The company has a market cap of $648.6 million and a price-to-earnings ratio of 40.33.

Repligen Corp. (NASDAQ:RGEN) last announced its earnings results on Monday, August 11th. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.06 by $0.03. The company had revenue of $15.60 million for the quarter, compared to the consensus estimate of $14.90 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. The company’s quarterly revenue was down 10.9% on a year-over-year basis. On average, analysts predict that Repligen Corp. will post $0.29 earnings per share for the current fiscal year.

Repligen Corporation is a United States-based life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs.

Receive News & Ratings for Repligen Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.